New Komodo Health + Kidney Cancer Association report shows how geography shapes burden, stage at diagnosis, and provider capacity.
Nearly 81,000 Americans will be newly diagnosed with kidney cancer this year, and incidence has continued to rise over the past two decades. But national statistics only tell part of the story. A patient’s experience with kidney cancer — when it’s diagnosed, how advanced it is, and how many providers are able to diagnose and treat it — can look very different depending on where they live.
Understanding these local differences is essential for improving patient outcomes. Strategies that work well in one region may fall short in another if they don’t account for variations in disease burden, patient demographics, or healthcare capacity.
To better understand these dynamics, Komodo Health has partnered with the Kidney Cancer Association (KCA) during National Kidney Awareness Month to examine kidney cancer across 10 major U.S. metropolitan areas. This analysis used Komodo’s healthcare-native AI analytics platform, Marmot™.
Where disease burden and system capacity diverge
The analysis revealed meaningful differences across metropolitan areas in both disease burden and healthcare capacity.
Rates of kidney cancer in these areas varied widely, ranging from approximately 123 cases per 100,000 people in Seattle to nearly 202 per 100,000 in Phoenix. Several West Coast metro areas, including the Bay Area and Seattle, exhibited a disproportionately high share of metastatic disease within their kidney cancer population. In these regions, more than 22% of patients were diagnosed with metastatic kidney cancer, compared with the national rate of 18.4%, with increases across age groups.
Patient age distributions also differed by region. In Atlanta, pediatric patients accounted for up to 1.8% of cases, higher than the metro average of 1.2%. In cities such as Chicago, Phoenix, and Durham-Chapel Hill, patients age 65 and older made up more than two-thirds of all cases.
In parallel, diagnostic capacity did not always track with disease burden. Some large metros combined lower metastatic shares with higher patient-to-provider ratios. For example, New York City had an average of 1.4 kidney cancer patients per diagnosing provider versus 1.1 across large metros, suggesting differences in diagnostic capacity and care pathways.
Seeing local patterns clearly and at scale
Capturing these insights across diverse regions is possible by using healthcare-native AI and consistent, auditable definitions to construct and compare clinically specific kidney cancer cohorts across metropolitan areas. Patient journeys were attributed at ZIP-level resolution, enabling standardized measurement of prevalence, metastatic disease, age gradients, and provider availability across markets.
This approach supports direct comparison at scale and rapid iteration, allowing analysts to move from question to insight without extended data engineering cycles.
Turning localized evidence into real-world impact
For researchers, advocates, and healthcare leaders, metro-level real-world evidence provides a clear understanding of where needs are greatest and where structural barriers may limit progress. Localized insights rather than national averages can better inform more targeted outreach, screening efforts, and resource allocation — strategies designed to meet patients where they are.
The full report provides an interactive view of kidney cancer variation across U.S. metropolitan areas and underscores the value of applying AI-enabled evidence to reduce disease burden and improve outcomes for people living with kidney cancer.
About Marmot: This analysis was conducted using Komodo Health’s Marmot, the first healthcare-native AI analytics platform, built on the industry’s most comprehensive real-world data and designed to deliver transparent, verifiable insights at unprecedented speed.
To see more articles like this, follow Komodo Health on X, LinkedIn, or YouTube, and visit Insights on our website.
